AstraZeneca/£AZN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
94,300
ISIN
GB0009895292
Website
AstraZeneca Metrics
BasicAdvanced
£160B
27.80
£3.71
0.18
£2.46
2.38%
Price and volume
Market cap
£160B
Beta
0.18
52-week high
£132.18
52-week low
£95.74
Average daily volume
1.8M
Dividend rate
£2.46
Financial strength
Current ratio
0.897
Quick ratio
0.694
Long term debt to equity
67.922
Total debt to equity
77.112
Dividend payout ratio (TTM)
63.60%
Interest coverage (TTM)
10.16%
Profitability
EBITDA (TTM)
13,630.256
Gross margin (TTM)
82.44%
Net profit margin (TTM)
14.14%
Operating margin (TTM)
24.75%
Effective tax rate (TTM)
16.26%
Revenue per employee (TTM)
£432,540
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
19.79%
Valuation
Price to earnings (TTM)
27.803
Price to revenue (TTM)
3.896
Price to book
3.89
Price to tangible book (TTM)
-9.04
Price to free cash flow (TTM)
23.295
Free cash flow yield (TTM)
4.29%
Free cash flow per share (TTM)
442.33%
Dividend yield (TTM)
2.38%
Growth
Revenue change (TTM)
15.48%
Earnings per share change (TTM)
22.71%
3-year revenue growth (CAGR)
9.84%
10-year revenue growth (CAGR)
7.72%
3-year earnings per share growth (CAGR)
90.42%
10-year earnings per share growth (CAGR)
17.24%
3-year dividend per share growth (CAGR)
2.60%
10-year dividend per share growth (CAGR)
1.02%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca raised its 2024 sales and profit forecast for the second time, driven by strong demand for cancer and rare disease medicines, and announced an additional $2 billion investment in U.S. R&D and manufacturing, creating 1,000 high-skilled jobs. (reuters.com)
The company reported a 24% increase in fourth-quarter revenue to $14.89 billion, surpassing analyst estimates, with oncology and respiratory treatments showing significant growth. (bloomberg.com)
AstraZeneca plans to invest $2.5 billion over five years to build a new R&D center in Beijing, enhancing its presence in the Chinese market and fostering collaborations in the life sciences sector. (finviz.com)
AstraZeneca's shares have fallen nearly 6% this year due to concerns over its Chinese business amid investigations, with recent events wiping out over $20 billion of its market value. (reuters.com)
The company faces potential fines in China of up to $4.5 million related to probes into alleged illegal imports of cancer drugs and data privacy breaches, which could impact its operations in the region. (bloomberg.com)
Analysts have raised concerns about AstraZeneca's growth outlook, noting that while revenue exceeded expectations, the sustainability of this performance is questionable due to reliance on collaboration revenues and lower operating leverage in 2024. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Jun 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £160B as of July 21, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 27.8 as of July 21, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is £2.456 and the yield is 2.38%. AstraZeneca has a payout ratio of 63.6% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.